Starpharma Holdings Limited (OTCMKTS:SPHRY) Sees Significant Decline in Short Interest

Starpharma Holdings Limited (OTCMKTS:SPHRY) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 2,600 shares, a drop of 42.2% from the October 31st total of 4,500 shares. Based on an average trading volume of 12,000 shares, the short-interest ratio is currently 0.2 days.

Starpharma Stock Performance

SPHRY stock remained flat at $0.67 on Friday. 50 shares of the company were exchanged, compared to its average volume of 5,499. The company has a current ratio of 4.94, a quick ratio of 4.58 and a debt-to-equity ratio of 0.07. Starpharma has a fifty-two week low of $0.52 and a fifty-two week high of $1.33. The company has a 50 day simple moving average of $0.68 and a two-hundred day simple moving average of $0.65.

About Starpharma

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom.